InterpretOmics India Pvt. Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
InterpretOmics India Pvt. Ltd. - overview
Established
2009
Location
Bangalore, Karnataka, India
Primary Industry
Software
About
InterpretOmics India Pvt. Ltd. is a biotechnology company specializing in advanced molecular biology tools and bioinformatics solutions, focusing on next-generation sequencing technologies to enhance research and diagnostics. Founded in 2009 and headquartered in Bangalore, India, InterpretOmics India Pvt.
Ltd. focuses on developing molecular biology tools. In September 2013, the company raised INR 99. 72 million in Angel funding from Amarante Shipping Pte.
Ltd. The company has not undergone any significant pivots or changes in business strategy and operates independently without any known parent or subsidiary companies. InterpretOmics specializes in the development and provision of advanced molecular biology tools and services, focusing on next-generation sequencing (NGS) technologies and bioinformatics solutions. Their core product offerings include engineered expression vectors designed for rapid cloning and expression of proteins, particularly in *E.
coli* systems. The company also provides reagents and consumables for NGS workflows, alongside diagnostic kits for various research and clinical applications. Their products are utilized by academic institutions, biotechnology firms, and pharmaceutical companies across North America, Europe, and Asia, addressing needs in protein production, genetic research, and disease diagnostics. In 2016, InterpretOmics recorded a revenue of INR 85,986, with an EBITDA amounting to -INR 704,379.
8. The company generates revenue primarily through the direct sale of its molecular biology products and services, including proprietary expression vectors and NGS-related reagents, typically via contracts with institutional clients and partnerships with biotechnology and pharmaceutical companies. InterpretOmics aims to leverage recent funding from the Angel round raised in September 2013 for future growth initiatives. This funding will support the development of new products, including advanced bioinformatics platforms and additional molecular biology tools targeted for release in the upcoming years.
The company plans to expand its market presence into Europe and North America by 2025, enhancing its offerings to meet the growing demands of the biotechnology sector.
Current Investors
Amarante Shipping Pte. Ltd.
Primary Industry
Software
Sub Industries
Analytics & Performance Software
Website
www.interpretomics.co
Verticals
Big Data
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
InterpretOmics India Pvt. Ltd. - financials
| Fiscal Year Ended | Mar 31, 2008 | Mar 31, 2009 | Mar 31, 2010 | Mar 31, 2011 | Mar 31, 2012 | Mar 31, 2013 | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 795,390 | 1,049,000 | 5,030,724 | 1,663,547 | - | - | - | - |
| % Revenue Growth (YoY) | - | - | 31.9% | 379.6% | (66.9%) | - | - | - | - |
| EBITDA (USD) | - | - | - | - | - | (1,770,016) | - | - | - |
| Operating Income (USD) | - | - | - | - | - | (2,077,573) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | - | 274,725.4 | 233,284 | 57,100.8 | 81,582 | (2,377,068) | - | - | - |
| % Net Margin | - | 34.5% | 22.2% | 1.1% | 4.9% | - | - | - | - |
InterpretOmics India Pvt. Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.